Related Experiment Videos
Pharmacokinetics of hemoglobin infusion
Progress in Clinical and Biological Research
|January 1, 1983
Summary
This study investigated hemoglobin pharmacokinetics in dogs, finding dose-dependent tissue deposition and non-linear elimination at high doses for SFH. Preliminary models suggest Michaelis-Menten elimination for PPHb.
Area of Science:
- Pharmacology
- Biomedical Engineering
Background:
- Acellular hemoglobin (Hb) solutions are researched for various applications.
- Published pharmacokinetic data for Hb solutions are highly variable.
- Establishing reliable pharmacokinetic models is crucial for Hb-based products.
Purpose of the Study:
- To develop pharmacokinetic models for Stroma-Free Hemoglobin (SFH) and a modified hemoglobin product.
- To analyze the impact of different doses on SFH pharmacokinetics.
- To characterize the elimination kinetics of Purity-Free Hemoglobin (PPHb).
Main Methods:
- Administered three dose levels of SFH (55, 111, 1400 mg/kg) via rapid intravenous injection to dogs.
- Collected serial blood samples and measured plasma Hb levels.
- Analyzed plasma concentration-time data using pharmacokinetic modeling, including single and multi-compartment models and Michaelis-Menten kinetics.
Main Results:
- SFH exhibited first-order decline at all doses, with dose-dependent volume of distribution suggesting increased tissue deposition at higher doses.
- Normalized AUC indicated non-linear elimination of SFH at high doses, consistent with known Hb elimination pathways.
- PPHb (650 mg/kg) followed a single-compartment model with Michaelis-Menten elimination.
Conclusions:
- SFH pharmacokinetics show dose-dependent tissue distribution and non-linear elimination at high concentrations.
- Preliminary pharmacokinetic models for SFH and PPHb have been established.
- Further research is required to validate and refine these pharmacokinetic models for Hb-based products.